Moving Forward after Major Stroke Trial: Endovascular Care for Some; More Research on Tap

Share

Joseph Broderick, MD, international stroke expert and Research Director of UCNI.
Photo by Mark Bowen Media.

Joseph Broderick, MD, Research Director at the UC Neuroscience Institute, was in the spotlight last week as the Principal Investigator of an international clinical trial that compared outcomes of stroke patients who received a clot-dissolving drug (tPA) through an IV and those who also received endovascular therapy. The endovascular treatment involved either delivering tPA directly to the clot via a catheter threaded up from the groin to the brain, or using a catheter and an FDA-approved device to actually retrieve the clot.

The clinical trial, the Interventional Management of Stroke III (IMS III), found that patients who received the high-tech endovascular treatment fared no better than those who received tPA through an IV, although the safety of the two approaches was very similar. The trial disappointed stroke specialists who had sought to provide a new solution to the problem of stroke caused by a blockage in major arteries supplying oxygen-rich blood to the brain.

Dr. Broderick, the Albert Barnes Voorheis Professor and Chair of UC’s Department of Neurology and Rehabilitation Medicine, authored the study, which appeared in the New England Journal of Medicine. He discussed the study and its ramifications with multiple media outlets, including the New York Times, the Los Angeles Times and the Washington Post, at the International Stroke Conference 2013 last week in Honolulu.

The study will likely change how some stroke patients are treated at the UC Neuroscience Institute, one of four institutes of the UC College of Medicine and UC Health. The majority of patients will continue to be treated with tPA through an IV, without additional endovascular care.  However, a subset of patients — those with large clots in large arteries — will strongly be considered for treatment with endovascular methods.

“Our study found that patients who have occlusions of the distal internal carotid artery did poorly with IV tPA and better with an endovascular approach, although the number of patients in that particular subgroup was small,” Dr. Broderick said.

Stroke patients may also benefit from two additional developments. The first is the UC Stroke Team’s effort to start endovascular therapy sooner, so as to maximize its benefits. “We have made efforts to minimize the time to start endovascular therapy since patients treated earlier tended to do better,” Dr. Broderick said. “We need to do an even better job with this.”

Andrew Ringer, MD

The second development involves improvements in the clot-retrieval devices themselves. “I think the new generation of devices is clearly better in opening arteries than what we had for most of the IMS III study,” said Andrew Ringer, MD, Director of the Division of Cerebrovascular Surgery and Professor of Neurosurgery & Radiology at UC. “I’ve seen a big difference in my own cases.”

Dr. Ringer and his colleagues at the Endovascular Neurosurgery Research Group, whose 20-plus members include the Mayo Clinic, Cornell University and the University of California, San Diego, have collected data on the effectiveness of a new FDA-approved flow-restoration device known as the Solitaire. A multi-center retrospective analysis of the self-expanding stent retriever was recently accepted by a peer-reviewed neurosurgical journal.

Dr. Broderick agreed that the newer devices open arteries better than those studied in the IMS III trial. A lingering question, however, is whether these improvements “will translate into better clinical outcomes for patients compared to IV tPA or standard therapy in patients who are beyond the tPA treatment window of 3 to 4 ½ hours.”

Pooja Khatri, MD

One thing is certain: the UC Stroke Team will continue to be at the center of international research into the best methods for treating patients who suffer acute stroke. “We remain very eager to participate in trials that test the combined tPA/endovascular and IV tPA alone approaches,” Dr. Broderick said. “We are participating in the Therapy Trial, which uses one of the new stent-retriever devices as well as a device that aspirates the clot. “We are also working on our next trial designs to improve rapid opening of brain arteries in acute stroke. These trials will include a combination of medications and advances in new mechanical devices.”

Pooja Khatri, MD, Associate Professor of Neurology and a neurologist at the UC Neuroscience Institute, is the medical principal investigator for the Therapy Trial, a multi-site U.S. study.

–Cindy Starr

This entry was posted in UC Gardner Neuroscience Blog and tagged , , , , , , , . Bookmark the permalink. Both comments and trackbacks are currently closed.
  • Print This Page
  • Make an Appointment: Schedule Now
  • Sign up for our newsletter!
  • UCNI Weekly Blog
  • Hope Stories

    • Brian’s Story: Meningioma

      Brian's Story: Meningioma “Carefree” is the word Brian uses to describe his life back then. He was 39 years old, happily married and the father of three children under the age of 5. “Life was busy, but that felt normal,” he says, reflecting. “The only...
    • Janis’s Story: Parkinson’s Disease

      Janis's Story: Parkinson's Disease When Janis Yelton gratefully enrolled in a ground-breaking study at the University of Cincinnati Gardner Neuroscience Institute, one of four institutes of the UC College of Medicine and UC Health, she was wracked by pain from advanced Parkinson’s disease, taking...
    • John’s Story: Epilepsy

      John's Story: Epilepsy In golf they call it a “bad lie.” A golfer strikes the ball, hoping to place it in a comfortable location on the fairway or the green, but the ball winds up somewhere else entirely – on the side of a...
    • Dale’s Hope Story: Parkinson’s

      Dale's Hope Story: Parkinson's [hana-flv-player video="/wp-content/videos/Dale_Ankeman_Sunflower_3.flv" width="500" height="377" description="" player="2" autoload="true" autoplay="false" loop="false" autorewind="true" /] After being diagnosed with Parkinson’s disease in 2003, 46-year-old Dale Ankenman was determined not to let it keep him off his bike. Considering his long list of credentials, including former...
    • Alison’s Story: Ruptured Aneurysm following Neurotrauma

      Alison's Story: Ruptured Aneurysm following Neurotrauma Step by hard-earned step, word by remembered word, Dr. Alison Delgado has recovered from a bicycle accident that nearly robbed her of her life. Dr. Delgado, who suffered serious physical and neurological injuries in the 2010 accident, is today a...
    • Sunny’s Story: A New MS Family

      Sunny's Story: A New MS Family As Sunny knows, one does not defeat multiple sclerosis. The disease is here today, and it is still here tomorrow. But with help from skilled,...
    • Charlie’s Story: Epilepsy

      Charlie's Story: EpilepsyBy Charlie Shor I have had many adventures in my 57 years, and I have accomplished much. But the main message of my story, which I have been given the opportunity to share, is that anything is possible. If you have...
    • Jim’s Story: Pituitary Tumor

      Jim's Story: Pituitary Tumor One turn of events led to another, and so it was that Jim, and not his wife, took Jim’s 87-year-old father to his appointment with the dermatologist for the first time. And so it was that the dermatologist was not...
    • Renee’s Story: Stroke

      Renee's Story: Stroke When 33-year-old high energy mother Renee Young became ill with the flu in November 2007, the last thing she expected was she was about to suffer a stroke. But that was exactly what happened. As she tried to swallow medication...
    • Adam’s Story: Post-accident Recovery

      Adam’s Story: Post-accident RecoveryAdam and two friends were tooling down the freeway on their motorcycles one fine Sunday last October when the accident occurred. Adam, who liked to feel the breeze on his shaved head, was not wearing a helmet. Changing lanes, he...